Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05551117
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:28.961252+00:00
Published At
2026-02-09T00:00:00+00:00
Record Updated At
2026-02-09
Results Posted At
2026-02-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Castration-Resistant Prostatic Cancer", "Androgen-Independent Prostatic Cancer", "Androgen-Insensitive Prostatic Cancer", "Androgen-Resistant Prostatic Cancer", "Hormone Refractory Prostatic Cancer", "Anal Cancer", "Anal Neoplasm", "Carcinoma, Squamous Cell of Head and Neck", "Head and Neck Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma", "Oral Squamous Cell Carcinoma", "Malignant Melanoma", "Melanoma", "Non-small Cell Lung Cancer", "Non-small Cell Carcinoma", "Small-cell Lung Cancer", "Small Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-09"
protocolSection.identificationModule.nctId
"NCT05551117"
protocolSection.identificationModule.officialTitle
"A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2026-02-09"

Study condition terms

  • Castration-Resistant Prostatic Cancer (protocolSection.conditionsModule.conditions)
  • Androgen-Independent Prostatic Cancer (protocolSection.conditionsModule.conditions)
  • Androgen-Insensitive Prostatic Cancer (protocolSection.conditionsModule.conditions)
  • Androgen-Resistant Prostatic Cancer (protocolSection.conditionsModule.conditions)
  • Hormone Refractory Prostatic Cancer (protocolSection.conditionsModule.conditions)
  • Anal Cancer (protocolSection.conditionsModule.conditions)
  • Anal Neoplasm (protocolSection.conditionsModule.conditions)
  • Carcinoma, Squamous Cell of Head and Neck (protocolSection.conditionsModule.conditions)
  • Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Laryngeal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Oral Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Malignant Melanoma (protocolSection.conditionsModule.conditions)
  • Melanoma (protocolSection.conditionsModule.conditions)
  • Non-small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Non-small Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Small-cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Small Cell Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.